Pralsetinib(LuciPral)

Pralsetinib is a prescription drug approved for marketing by the U.S. Food and Drug Administration (FDA) in September 2020. It is indicated for targeting RET gene fusions (e.g., KIF5B-RET, CCDC6-RET) and activating mutations (e.g., RET V804L/M, M918T), and its use shall be strictly in accordance with the doctor’s instructions.

Lucius Related Certificates

Drug Testing Report

Drug Approval Certificate

Targets of Action

RET gene fusions (e.g., KIF5B-RET, CCDC6-RET) and activating mutations (e.g., RET V804L/M, M918T).

Mechanism of Action

Pralsetinib can block the uncontrolled proliferation induced by abnormally mutated RET genes in cancer cells.

Dosage and Administration

Administration route and frequency of Pralsetinib: Oral administration, once daily.

The dosage of Mavacamten should be adjusted according to the patient’s actual condition. For specific circumstances, patients should consult a doctor and strictly follow the medical advice.

Recommended Reading: Dosage and Administration of Pralsetinib

Adverse Reactions

Common adverse reactions (≥25%) include musculoskeletal pain, constipation, hypertension, diarrhea, fatigue, edema, fever, and cough.

Reference Article: Adverse Reactions of Pralsetinib

Medication Use in Special Populations

Pediatric Use: Epiphyseal growth plates should be monitored in adolescent patients. If abnormalities occur, consider interrupting or discontinuing GAVRETO.

Lactation: Women are advised not to breastfeed during GAVRETO treatment and within 1 week after the last dose.

Daily Precautions

Remember to take Pralsetinib capsules as instructed by your doctor.

Do not alter the dosage or discontinue Pralsetinib unless directed by a healthcare provider.

from FDA，2024.03